Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•16/11/2026•08:00 ET
0
Key Highlights
- ➤NMRA-215 IND application submitted to FDA for obesity and cardiometabolic disease
- ➤NMRA-215 delivered up to 19% monotherapy weight loss in obese mice
- ➤NMRA-511 30 mg BID showed dose-proportional exposure and no serious adverse events
- ➤Neumora reported $34.4 million third-quarter net loss versus $56.8 million
- ➤Cash fell to $85.7 million; company warns substantial additional funding is required
Expert Statements
Joshua Pinto, Ph.D., President and chief executive officer of Neumora Therapeutics
“We’ve been in a period of strong execution across our pipeline, including the submission of our IND for NMRA-215 in obesity and the NMRA-511 data we reported today, which suggest we can build on the unsurpassed efficacy seen in our Phase 1b study in AD agitation,”
Joshua Pinto, Ph.D., President and chief executive officer of Neumora Therapeutics
“We remain disciplined in allocating capital to the programs with the greatest potential to create value for patients and shareholders, and we are actively evaluating options to fund our lead programs through their next value inflection points.”
IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration
Dose-proportional increase in exposure observed in multiple ascending dose (MAD) expansion cohort with NMRA-511 (V1aR antagonist), suggesting potential to build on the efficacy profile demonstrated in Phase 1b study
Get started
Create a free account to read the full story.
